SCHEDULE 13D/A: Perceptive Entities Disclose 20.9% Stake in Trinity Biotech plc
Beneficial Ownership Disclosure
Perceptive Advisors and its affiliates have filed an amended Schedule 13D, revealing a combined beneficial ownership of 20.9% in Trinity Biotech plc, including shares from warrant exercises.
Summary
- Perceptive Advisors LLC, Perceptive Credit Advisors LLC, and Joseph Edelman collectively reported beneficial ownership of 85,800,000 Class A Ordinary Shares of Trinity Biotech plc.
- This aggregate ownership represents 20.9% of Trinity Biotech plc's Class A Ordinary Shares outstanding.
- The percentage is calculated based on 361,073,562 Ordinary Shares outstanding as of November 30, 2024, as reported in Trinity Biotech plc's prospectus filed on December 5, 2024.
- The reported ownership includes shares assumed from the exercise of warrants: 10,000,000 Ordinary Shares from 500,000 Warrants held by Perceptive Credit Holdings II, L.P., and 40,000,000 Ordinary Shares from 2,000,000 Warrants held by Perceptive Credit Holdings III, L.P.
- Perceptive Credit Holdings II, L.P. separately reported beneficial ownership of 45,800,000 shares, representing 11.4% of the class.
- Perceptive Credit Holdings III, L.P. separately reported beneficial ownership of 40,000,000 shares, representing 9.7% of the class.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing disclosing beneficial ownership and does not contain information that inherently indicates a positive or negative sentiment towards the company's performance or outlook.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
The document does not contain any forward-looking statements or guidance regarding Trinity Biotech plc's future performance or strategic direction from either the company or the reporting persons.
Industry Context
This filing is a disclosure of a significant investor stake and does not provide analysis of broader industry trends or competitive landscape within the healthcare diagnostics sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can influence market perception and potentially share price.
Key Dates
| Date | Description |
|---|---|
| 2024-11-30 | Date as of which 361,073,562 Ordinary Shares were reported outstanding by the Issuer. |
| 2024-12-05 | Date of Issuer's prospectus filing pursuant to Rule 424(b)(3) with the SEC. |
| 2024-12-31 | Date of event which required the filing of this statement. |
| 2025-02-14 | Date of filing of this Amendment No. 3 to Schedule 13D. |
Keywords
Trinity Biotech, Perceptive Advisors, Schedule 13D, beneficial ownership, Class A Ordinary Shares, SEC filing, institutional investor, warrants, healthcare diagnostics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.